



US008476284B2

(12) **United States Patent**
Honigberg et al.

(10) **Patent No.:** **US 8,476,284 B2**
(b5) **Date of Patent:** ***Jul. 2, 2013**

(54) **INHIBITORS OF BRUTON'S TYROSINE KINASE**(75) Inventors: **Lee Honigberg**, San Francisco, CA (US); **Erik Verner**, Belmont, CA (US); **Zhengying Pan**, Austin, TX (US)(73) Assignee: **Pharmacyclics, Inc.**, Sunnyvale, CA (US)

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days.

This patent is subject to a terminal disclaimer.

(21) Appl. No.: **13/328,718**(22) Filed: **Dec. 16, 2011**(65) **Prior Publication Data**

US 2012/0108612 A1 May 3, 2012

Related U.S. Application Data

(60) Continuation of application No. 13/312,606, filed on Dec. 6, 2011, which is a continuation of application No. 13/249,066, filed on Sep. 29, 2011, which is a continuation of application No. 12/356,498, filed on Jan. 20, 2009, now Pat. No. 8,088,781, which is a division of application No. 11/617,645, filed on Dec. 28, 2006, now Pat. No. 7,514,444.

(60) Provisional application No. 60/826,720, filed on Sep. 22, 2006, provisional application No. 60/828,590, filed on Oct. 6, 2006.

(51) **Int. Cl.****A01N 43/90** (2006.01)
A61K 31/519 (2006.01)(52) **U.S. Cl.**USPC **514/262.1**(58) **Field of Classification Search**

None

See application file for complete search history.

(56) **References Cited****U.S. PATENT DOCUMENTS**

5,397,787 A	3/1995	Buzzetti
6,160,010 A	12/2000	Uckun et al.
6,221,900 B1	4/2001	Uckun et al.
6,326,469 B1	12/2001	Ullrich et al.
6,506,769 B2	1/2003	Snow et al.
6,660,744 B1	12/2003	Hirst et al.
6,753,348 B2	6/2004	Uckun et al.
6,770,639 B2	8/2004	Snow et al.
6,921,763 B2	7/2005	Hirst et al.
7,138,420 B2	11/2006	Bentzien et al.
7,332,497 B2	2/2008	Hirst et al.
7,514,444 B2	4/2009	Honigberg et al.
7,718,662 B1	5/2010	Chen
7,732,454 B2	6/2010	Verner
7,741,330 B1	6/2010	Chen
7,825,118 B2	11/2010	Honigberg et al.
7,960,396 B2	6/2011	Honigberg et al.
8,008,309 B2	8/2011	Honigberg et al.
8,088,781 B2	1/2012	Honigberg et al.
8,158,786 B2	4/2012	Honigberg et al.
8,232,280 B2	7/2012	Honigberg et al.
8,236,812 B2	8/2012	Honigberg et al.

2002/0016460 A1	2/2002	Snow et al.
2002/0155505 A1	10/2002	Wells et al.
2003/0013125 A1	1/2003	Braisted et al.
2003/0040461 A1	2/2003	Mcatee
2003/0125235 A1	7/2003	Foxwell
2004/0006083 A1	1/2004	Hirst et al.
2005/0008640 A1	1/2005	Waegell et al.
2005/0084905 A1	4/2005	Prescott et al.
2005/0090499 A1	4/2005	Currie et al.
2005/0101604 A1	5/2005	Currie et al.
2005/0196851 A1	9/2005	Uckun
2005/0209255 A1	9/2005	Jimenez et al.
2006/0079494 A1	4/2006	Santi et al.
2006/0167090 A1	7/2006	Uckun et al.
2007/0281907 A1	12/2007	Watkins
2008/0214501 A1	9/2008	Pan

(Continued)

FOREIGN PATENT DOCUMENTS

EP	1473039	11/2004
WO	WO-97-28161	8/1997

(Continued)


OTHER PUBLICATIONS

U.S. Appl. No. 13/654,173, filed Oct. 17, 2012, Honigberg et al.
U.S. Appl. No. 13/736,812, filed Jan. 8, 2013, Buggy et al.
U.S. Appl. No. 13/747,322, filed Jan. 22, 2013, Buggy et al.
U.S. Appl. No. 13/747,319, filed Jan. 22, 2013, Buggy et al.
Advani et al. "The BTK inhibitor PCI-32765 is highly active and well tolerated in patients (PTS) with relapsed/refractory B cell malignancies: final results from a phase I study", Ann. Oncol., 22(suppl 4): abstract 153 (2011).
Apsel et al. "Targeted Polypharmacology: Discovery of Dual Inhibitors of Tyrosine and Phosphoinositide Kinases." Nature Chem. Bio., 4(11):691-699 (2008).

(Continued)

Primary Examiner — Jeffrey Murray**(74) Attorney, Agent, or Firm — Wilson, Sonsini, Goodrich & Rosati****(57) ABSTRACT**

Disclosed herein are compounds, including compounds having the Formula (A)



Formula (A)

where A, R1, R2, R3, and R4 are as defined in the specification, that form covalent bonds with Bruton's tyrosine kinase (Btk). Also described are irreversible inhibitors of Btk. Methods for the preparation of the compounds are disclosed. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the Btk inhibitors are disclosed, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.